DexCom, Inc. - DXCM STOCK NEWS

Dexcom (NASDAQ: DXCM) announced that its Executive Vice President and Chief Financial Officer, Jereme Sylvain, will present an update at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.

The presentation will start at 4:20 PM EST and will be available via live webcast. The webcast can be accessed through the Dexcom Investor Relations website and will be archived for future reference.

Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.

This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.

Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.

This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.

Dexcom has launched the Dexcom ONE+ sensor in the UK, incorporating 25 years of research to assist individuals with Type 2 diabetes in monitoring their glucose levels in real-time. The first-ever 'Dexcom State of Type 2 Report' reveals that a significant number of people with Type 2 diabetes experience anxiety and depression, and many struggle to manage their condition effectively. The report highlights that 54% of respondents wish they had more confidence in managing their diabetes, and 63% face challenges in improving their diet or mental health. Additionally, 48% of participants believe glucose monitoring could improve their condition management.

Dexcom ONE+ aims to provide a tailored solution for people with Type 2 diabetes, enhancing user motivation and diabetes management by providing real-time feedback. The report is intended to serve as a resource for healthcare professionals and empower those with Type 2 diabetes to feel less isolated.

Dexcom, Inc. (Nasdaq: DXCM) reported strong financial results for the first quarter of 2024, with revenue growing 24% year-over-year to $921.0 million. The company's U.S. and international revenue also saw significant growth. Dexcom received FDA clearance for its new CGM system, launched new products in European countries, and published its annual Sustainability Report. The company's operating income and net income showed substantial increases, reflecting a positive outlook for the future.

DexCom, Inc. releases its annual Sustainability Report, showcasing advancements in corporate sustainability disclosures, including expanded greenhouse gas emissions data and increased transparency in pay-equity practices. The report highlights key initiatives aligned with Dexcom's core values and business strategy, emphasizing its commitment to stakeholders and global health through access to CGM technology.

DexCom, Inc. (DXCM) plans to release its first quarter 2024 financial results on April 25, 2024. A conference call will be held to review the performance, starting at 4:30 p.m. (Eastern Time) on the same day.

DexCom, Inc. (NASDAQ:DXCM) announces FDA clearance for Stelo, the first glucose biosensor in the US that doesn't require a prescription. Stelo, a small wearable sensor worn on the back of the upper arm, will provide glucose insights directly to a user's smartphone. Created by the makers of Dexcom G7, Stelo aims to empower people with Type 2 diabetes not using insulin to take control of their health. Available summer 2024, Stelo will cater to the approximately 25 million people in the US living with Type 2 diabetes who do not use insulin and can benefit from continuous glucose monitoring technology.

DexCom, Inc. announced new clinical evidence supporting the use of continuous glucose monitoring (CGM) for automated insulin delivery systems, showcasing benefits for Type 2 diabetes management and reduced mortality in Type 1 and Type 2 diabetes. The company launched G7 in 16 new markets and Dexcom ONE+ in eight markets, with 'Direct-to-watch' functionality for Apple Watch. Dexcom's AID systems, in partnership with Tandem and Insulet, demonstrated significant health outcomes with low event rates of severe hypoglycaemia and diabetic ketoacidosis. Clinical studies also highlighted the effectiveness of CGM in improving HbA1c and glucose range for Type 2 diabetes. Dexcom continues to innovate and expand access to its CGM technology globally.

DexCom, Inc. (DXCM) will present an update at the 45th Annual Raymond James Institutional Investors Conference. The live presentation by Sean Christensen, VP of Finance and Investor Relations, will be webcasted on March 5th.